Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
This content is for Standard 1 Year members only. LoginJoin Now